BioSpace News Archive

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2018.

Chairman Bishop, Ranking Member Fortenberry, and members of the subcommittee.

Aflac Incorporated announced that Executive Vice President and Chief Financial Officer of Aflac Incorporated Frederick J. Crawford will participate in a fireside chat at the Raymond James 40th Annual Institutional Investors Conference on March 6, 2019 at 8:05 a.m. ET.

Novel composition design allows for systemic delivery of TLR8 with activity localized to HER2-expressing tumors

Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models

Consolidated Results of Operations, As Reported and As Adjusted - Three-month periods ended December 31, 2018 and 2017:

Syros Pharmaceuticals announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research Annual Meeting taking place March 29-April 3 in Atlanta.

Syndax Pharmaceuticals, Inc. announced two oral presentations at the upcoming American Association for Cancer Research Annual Meeting being held March 29 - April 3, 2019 in Atlanta, Georgia.

Endo International plc announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc.

Tolero Pharmaceuticals, Inc. announced that new data from five abstracts on the company’s pipeline of investigational agents will be presented at the American Association for Cancer Research Annual Meeting, taking place March 29-April 3, 2019 in Atlanta, Georgia.